| アブストラクト | INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1. Despite efficacy, GLP-1 RAs are associated with adverse reactions across multiple organ systems. To address the gap in class-wide comparative safety analyses beyond previous studies limited to single drugs or organ systems, this study systematically evaluated adverse events for all approved GLP-1 RAs to identify hidden risks and support clinical decision-making. METHODS: We conducted a disproportionality analysis using the World Health Organization pharmacovigilance database (VigiBase) data up to January 2025. Reporting odds ratio (ROR) and information component (IC) were calculated for seven GLP-1 RAs. Signals were considered significant when ROR(025) > 1 and IC(025) > 0. Subgroup analyses were stratified by gender and age. We aimed to synthesize and analyze existing randomized controlled trials (RCT) to validate VigiBase mining results. RESULTS: Among 348,649 reports, gastrointestinal disorders were the most frequent System Organ Class. Notable signals included tirzepatide with "abdominal pain" (ROR(025) = 53.54), liraglutide with "drug ineffective" (ROR(025) = 31.14) and "pancreatitis" (ROR(025) = 4.24), exenatide with "injection site pain" (ROR(025) = 70.14), and albiglutide with "device use error" (ROR(025) = 1424.33). Male patients and younger adults (18-44 years) generally showed higher positive reporting rates. CONCLUSIONS: This study provides a comprehensive safety comparison across all seven approved GLP-1 RAs, confirming known risks and revealing drug-specific signals-such as injection-related issues and paradoxical hyperglycemia. These findings aid personalized treatment strategies and post-marketing surveillance. |
|---|
| ジャーナル名 | Diabetes therapy : research, treatment and education of diabetes and related disorders |
|---|
| Pubmed追加日 | 2026/4/21 |
|---|
| 投稿者 | Li, Jiaxun; Liang, Jizhou; Zhang, Wei; He, Jia; Ye, Xiaofei |
|---|
| 組織名 | Faculty of Military Health Service, Naval Medical University, Shanghai, China.;Graduate School of Naval Medical University, Shanghai, China.;hejia63@yeah.net.;yexiaofei@smmu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42012593/ |
|---|
